thought posit uterin fibroid data
 expect strength myov share morn given posit result relugolix phase liberti studi uterin fibroid
uf meet primari endpoint ith omen achiev respond criteria menstrual blood loss vs placebo
respond rate low er seen smaller phase studi line ith
rate seen phase studi abbvi orilissa elagolix plu add-back arm notabl bone miner densiti loss rate
 ere similar betw een treatment placebo arm support benefit includ add-back therapi recal bullish
outlook myovant relugolix physician survey basi recent upgrad biopharmaceut omen
health survey posit abbv/nbix hile trial fairli derisk prior data approv japan still
view today data signific posit myovant derisk program advanc second phase trial uf
liberti ith data expect anticip similarli posit data liberti follow ed nda submiss
launch reiter ow rate pt
myovant hold confer call discuss result et dial-in
market opportun larg take time build hile market uf ill built ground view
sizabl enough opportun relugolix abbvi orilissa ith peak sale estim view
orilissa market prior relugolix neg fact allow much market educ
myovant enter still expect steadi launch ramp ith revenu vs consensu revenu
vs uterin fibroid
liberti summari recal liberti intern phase random double-blind placebo-control efficaci
safeti studi evalu eek oral relugolixw ith tw differ cours add-back therapi low -dose estradiol
norethindron acet vs placebo omen ith heavi menstrual bleed associ ith uterin fibroid studi met
primari endpoint ith omen respond vs placebo group respond averag
reduct menstrual blood loss among key secondari endpoint bone miner densiti outcom ere
betw een activ placebo arm secondari endpoint ere similarli posit includ reduct pain
improv qol amenorrhea anemia reduct uterin volum rate ere similar betw een
relugolix treatment group vs respect ere rate discontinu due vs respect
among occur particip common treatment arm hot flush vs respect
coverag myovant women health space
myovant scienc ltd upgrad overw eight pt
slide omen health survey see link
 biopharmaceut omen health survey posit abbv/nbix
myov take present
abbv/nbix thought orilissa elagolix approv
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog valu use discount cash flow analysi assum impli intrins
valu per share
risk may imped achiev barclay research valuat price biosimilar make greater
headw ay market cannib share humira could potenti face addit dow nside risk humira current
compris total sale declin drug outlook could sever impact earn addit hcv
portfolio could fail captur share exist competit also imbruvica could limit label expans oncolog
grow th may meet expect pipelin failur could also drive dow nside
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog price target per share base npv analysi forecast risk adjust sale
relugolix assum patent expir ith year hatch-w axman exclus extens assum
termin valu includ sale omen health indic uf em line ith biotech similar size
development stage assum discount rate product launch year follow ing plan read out
phase trial uterin fibroid endometriosi base assumpt deriv valuat compris
relugolix us sale eu sale omen health net cash
risk may imped achiev barclay research valuat price clinic development
risk myovant lead asset relugolix mid-stag develop uterin fibroid uf endometriosi advanc
prostat cancer despit encourag posit phase data indic guarante pivot phase studi
 ill demonstr posit clinic meaning outcom failur indic especi uterin fibroid
market risk smid-cap biotechnolog histor volatil relugolix light catalyst calendar balanc
year hich may exagger dynam investor may opt put capit ork outsid myov share near
term hich may neg impact compani share
regulatori risk nda file relugolix uf endometriosi expect late assum posit phase
data asset ould expect indic grant approv ever fda may approv agent
agenc may fail ithin expect timelin delay inabl gain approv ould significantli pressur myov
commerci risk myovant plan launch relugolix us europ omen potenti
advanc prostat cancer myovant experi commerci drug ould need build commerci
infrastructur hich could prove challeng prevent myovant maxim drug commerci opportun failur
relugolix gain meaning market share compet effect could pressur myov share
reimburs risk relugolix develop treatment endometriosi uterin fibroid advanc prostat
cancer develop current behind drug ithin class elagolix could gain signific market share approv
addit gener leuprolid acet avail indic current sell cost brand lupron
 hile believ relugolix offer meaning differenti payor may requir use gener lupron ahead relugolix use
mechan limit drug penetr market durat includ mandat use elagolix vs relugolix
rate price target histori
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
